Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA4 | P22748 | 3/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA5A | P35218 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | DAO | P14920 | 3/20 | 0.41 |
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7086293 | 1.00 | CA1 (0.43) | CA1CA4CA14CA12CA5A | |
| SCHEMBL7081405 | 0.83 | CYP3A4 (0.54) | CA1CA4CA14CA12CA5A | |
| SCHEMBL7081400 | 0.83 | CYP3A4 (0.54) | CA1CA4CA14CA12CA5A | |
| SCHEMBL18214413 | 0.75 | CYP3A4 (0.60) | CA1CA4CA14CA12CA5A | |
| SCHEMBL5672665 | 0.74 | CYP3A4 (0.73) | DAOTAAR1MAOACYP3A4 | |
| SCHEMBL5672669 | 0.74 | CYP3A4 (0.73) | DAOTAAR1MAOACYP3A4 | |
| SCHEMBL5672688 | 0.73 | DAO (0.41) | DAOTAAR1MAOAMAOBCYP3A4 | |
| SCHEMBL7086021 | 0.69 | HTR2A (0.42) | CA1CA4CA14CA12CA5A | |
| SCHEMBL2401895 | 0.68 | PDCD4 (0.49) | CA1CA4CA14CA12CA5A | |
| SCHEMBL14496504 | 0.68 | PDCD4 (0.49) | CA1CA4CA14CA12CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030236302-A1 | Synthetic derivatives | SYNTA PHARMACEUTICALS CORP. | 2003-12-25 | — | — | US | disclosed |
| WO-2003072103-A1 | SYNTHETIC DERIVATIVES | KAVA PHARMACEUTICALS, INC. (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236302-A1 | Synthetic derivatives | CBR1, CBR3, REL | CA1 3659/4885CA4 1186/4885CA14 3923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.